Dr. Michael Keng
Claim this profileUniversity of Virginia Cancer Center
Studies Acute Myeloid Leukemia
Studies Leukemia
11 reported clinical trials
20 drugs studied
Area of expertise
1Acute Myeloid Leukemia
FLT3 positive
D835 positive
2Leukemia
CD-22 positive
Philadelphia chromosome negative
Affiliated Hospitals
Clinical Trials Michael Keng is currently running
BST-236 + Venetoclax
for Acute Myeloid Leukemia
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be followed with up to 3 maintenance courses with BST-236 alone. Patients will be followed for 1 year in the study and additional 1 year in post study follow-up
Recruiting1 award Phase 1 & 2
Crenolanib vs Midostaurin
for Acute Myeloid Leukemia
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.
Recruiting3 awards Phase 3
More about Michael Keng
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Michael Keng has experience with
- Venetoclax
- DFP-10917
- Azacitidine
- Inotuzumab Ozogamicin
- BST-236
- Ipilimumab
Breakdown of trials Michael Keng has run
Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Keng specialize in?
Michael Keng focuses on Acute Myeloid Leukemia and Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved FLT3 positive patients, or patients who are D835 positive.
Is Michael Keng currently recruiting for clinical trials?
Yes, Michael Keng is currently recruiting for 4 clinical trials in Charlottesville Virginia. If you're interested in participating, you should apply.
Are there any treatments that Michael Keng has studied deeply?
Yes, Michael Keng has studied treatments such as Venetoclax, DFP-10917, Azacitidine.
What is the best way to schedule an appointment with Michael Keng?
Apply for one of the trials that Michael Keng is conducting.
What is the office address of Michael Keng?
The office of Michael Keng is located at: University of Virginia Cancer Center, Charlottesville, Virginia 22903 United States. This is the address for their practice at the University of Virginia Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.